Skip to main content

Table 3 Data in patients with fibrosis stage ≥ vs. < 3

From: Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

  Fibrosis stage ≥ 3
n = 27
Fibrosis stage < 3
n = 33
p value
Age at biopsy (yrs) 40.6 ± 8.7 38.3 ± 7.8 ns
Age exposed to HCV (yrs) 20.3 ± 11.0 24.4 ± 7.2 ns
Age at HIV diagnosis (yrs) 33.6 ± 9.6 33.1 ± 6.7 ns
HIV diagnosed in or after 1996 11 (41%) 23 (70%) 0.023
White 8 (30%) 15 (45%) ns
Alcohol 6 (22%) 12 (36%) ns
Diabetes Mellitus 1 (4%) 2 (6%) ns
Weight 70.7 ± 10.0 73.5 ± 10.2 ns
Weight ≥ 75 Kg 11 (41%) 13 (39%)  
Cholestrol 4.5 ± 1.3 4.0 ± 1.0 ns
Triglycerides (TG) 2.1 ± 1.8 1.8 ± 1.5 ns
Cholestrol/TG ratio 5.0 ± 2.2 3.8 ± 1.3 0.02
Platelet count (/mm3) 163 ± 65.5 228 ± 66.8 0.001
Therapy received    
None 5 (18%) 12 (36%) Ns
NRTI 4 (15%) 6 (18%) Ns
Duration 11.2 ± 8.4 29.3 ± 17.1 0.16
Only HAART 11 (41%) 11 (33%) Ns
Duration 29.5 ± 26.5 30.4 ± 27.9 Ns
Sequential 7 (26%) 4 (12%) Ns
Duration 105 ± 23.3 77.5 ± 47.3 0.39
Steatosis 18 (67%) 17 (51%) Ns
Steatosis grade 1.0 ± 0.9 0.5 ± 0.5 0.028
Necroinflammatory grade 4.4 ± 1.9 3.1 ± 1.3 0.007
CD4 count (/mm3) 370 (130–1100) 510 (100–1200) 0.06
HIV VL (copies/ml) UD (UD-210955) 28.5 (UD-59540) Ns
  1. UD: undetectable